Schumpelick V, Dreuw B, Ophoff K, Fass J
Chirurgische Klinik, Medizinischen Fakultät, Rheinisch-Westfälische Technische Hochschule (RWTH), Aachen.
Leber Magen Darm. 1996 Mar;26(2):75-6, 79-80, 83-6.
To investigate the surgical results of adenocarcinoma of the esophagus and esophagogastric junction and its relationship with gastroesophageal reflux disease (GERD) and Barrett's esophagus.
The incidence of adenocarcinoma of the cardia is continuously rising. Specialized intestinal metaplasia in Barrett's esophagus seems to be the source of these tumors. Barrett's esophagus is end stage GERD. In experimental studies alkaline reflux give rise of Barrett's esophagus and adenocarcinoma.
122 patients with adenocarcinoma of the cardia and 121 patients with squamous cell tumor of the esophagus.
All esophageal resections between 11/85 and 2/95 were retrospectively analyzed. The relationship of gastroesophageal reflux disease, Barrett's esophagus and malignancy was compared between both groups using parameters of case history and histological sections. Survival was analyzed for tumorstage, T-and N-stage and R-classification.
5.9% of the adenocarcinomas were stage I, 44.1% stage II, 41. 5% stage III and 8.5% stage IV. Heartburn, regurgitation, consumption of H2 blockers or Barrett's mucosa were significantly more frequent for adenocarcinomas. A 5 year survival of 100% was seen for stage I tumors. Invasion of t he muscular layer reduced survival to 50%, lymph node invasion to 20%. R0-resection had a survival of 40%.
A relationship of GERD and adenocarcinoma of the cardia seems to be likely in our cases. Most patients had advanced malignancy. Survival is good only for early cases. Prevention of tumor genesis with effective antireflux surgery in case of alkaline reflux seem to be the best therapeutic decision.
探讨食管及食管胃交界腺癌的手术结果及其与胃食管反流病(GERD)和巴雷特食管的关系。
贲门腺癌的发病率持续上升。巴雷特食管中的特殊肠化生似乎是这些肿瘤的来源。巴雷特食管是GERD的终末期。在实验研究中,碱性反流会引发巴雷特食管和腺癌。
122例贲门腺癌患者和121例食管鳞状细胞肿瘤患者。
对1985年11月至1995年2月期间所有的食管切除术进行回顾性分析。使用病史和组织学切片参数比较两组患者胃食管反流病、巴雷特食管与恶性肿瘤之间的关系。分析肿瘤分期、T分期、N分期和R分级的生存率。
5.9%的腺癌为I期,44.1%为II期,41.5%为III期,8.5%为IV期。腺癌患者出现烧心、反流、使用H2阻滞剂或巴雷特黏膜的情况明显更为频繁。I期肿瘤的5年生存率为100%。侵犯肌层会使生存率降至50%,有淋巴结侵犯则降至20%。R0切除的生存率为40%。
在我们的病例中,GERD与贲门腺癌之间似乎存在关联。大多数患者患有晚期恶性肿瘤。仅早期病例的生存率良好。对于碱性反流的情况,通过有效的抗反流手术预防肿瘤发生似乎是最佳治疗决策。